Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Lanthanum
All products: not a benefit
Nat-Lanthanum · DIN 02498731 · 250 mg · chewable tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Nat-Lanthanum · DIN 02498731
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 250 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Lanthanum: Formulary list price $1.20 per unit (the source does not state the unit; exact figure $1.2034). What the ministry pays, not the patient.
Ministry pays: $1.2034 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498731).
DIN 02498731: Nat-Lanthanum
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800005; group id 550; item number 1482; lccId None; manufacturer id NAT
Source form: Chew Tab; strength: 250mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.2034; ministry $1.2034
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498731
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98843Interchangeable products
Fosrenol · DIN 02287145 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498731
Shortage record checked October 6, 2026
Nat-Lanthanum · DIN 02498758 · 500 mg · chewable tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Nat-Lanthanum · DIN 02498758
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 500 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Lanthanum: Formulary list price $2.41 per unit (the source does not state the unit; exact figure $2.4069). What the ministry pays, not the patient.
Ministry pays: $2.4069 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498758).
DIN 02498758: Nat-Lanthanum
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800006; group id 550; item number 1483; lccId None; manufacturer id NAT
Source form: Chew Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $2.4069; ministry $2.4069
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498758
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98844Interchangeable products
Fosrenol · DIN 02287153 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498758
Shortage record checked October 6, 2026
Nat-Lanthanum · DIN 02498766 · 750 mg · chewable tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Nat-Lanthanum · DIN 02498766
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 750 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Lanthanum: Formulary list price $3.62 per unit (the source does not state the unit; exact figure $3.6219). What the ministry pays, not the patient.
Ministry pays: $3.6219 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498766).
DIN 02498766: Nat-Lanthanum
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800007; group id 550; item number 1484; lccId None; manufacturer id NAT
Source form: Chew Tab; strength: 750mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $3.6219; ministry $3.6219
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498766
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98845Interchangeable products
Fosrenol · DIN 02287161 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498766
Shortage record checked October 6, 2026
Nat-Lanthanum · DIN 02498774 · 1000 mg · chewable tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Nat-Lanthanum · DIN 02498774
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 1000 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Lanthanum: Formulary list price $4.80 per unit (the source does not state the unit; exact figure $4.8018). What the ministry pays, not the patient.
Ministry pays: $4.8018 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498774).
DIN 02498774: Nat-Lanthanum
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 401800008; group id 550; item number 1485; lccId None; manufacturer id NAT
Source form: Chew Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $4.8018; ministry $4.8018
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02498774
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98846Interchangeable products
Fosrenol · DIN 02287188 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498774
Shortage record checked October 6, 2026
Fosrenol · DIN 02287145 · 250 mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-04-25 — choose a marketed DIN from the same-category list.Discontinued April 25, 2023 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-04-25 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2023-04-25 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Fosrenol · DIN 02287145
Manufacturer: Takeda Canada Inc.; listing date 2020-08-28
Health Canada: Cancelled post market since 2023-04-25 · brand FOSRENOL · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE HYDRATE) 250 MG · company Takeda canada inc · schedule Prescription
DIN 02287145: Fosrenol
Raw flags: notABenefit=Y, sec3=Y
Item: 401800005; group id 550; item number 1482; lccId None; manufacturer id TAK
Source form: Chew Tab; strength: 250mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287145
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77258Interchangeable products
Nat-Lanthanum · DIN 02498731 · $1.2034
Shortage status: discontinued (April 30, 2023, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287145
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 25, 2023 — choose a marketed DIN from the same-category list.
Fosrenol · DIN 02287153 · 500 mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-10 — choose a marketed DIN from the same-category list.Discontinued June 10, 2024 · checked November 17, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-10 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2024-06-10 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Fosrenol · DIN 02287153
Manufacturer: Takeda Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2024-06-10 · brand FOSRENOL · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE HYDRATE) 500 MG · company Takeda canada inc · schedule Prescription
DIN 02287153: Fosrenol
Raw flags: notABenefit=Y, sec3=Y
Item: 401800006; group id 550; item number 1483; lccId None; manufacturer id TAK
Source form: Chew Tab; strength: 500mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287153
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77259Interchangeable products
Nat-Lanthanum · DIN 02498758 · $2.4069
Shortage status: discontinued (June 10, 2024, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287153
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 10, 2024 — choose a marketed DIN from the same-category list.
Fosrenol · DIN 02287161 · 750 mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Fosrenol · DIN 02287161
Manufacturer: Takeda Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2024-07-31 · brand FOSRENOL · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE HYDRATE) 750 MG · company Takeda canada inc · schedule Prescription
DIN 02287161: Fosrenol
Raw flags: notABenefit=Y, sec3=Y
Item: 401800007; group id 550; item number 1484; lccId None; manufacturer id TAK
Source form: Chew Tab; strength: 750mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287161
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77260Interchangeable products
Nat-Lanthanum · DIN 02498766 · $3.6219
Shortage status: discontinued (July 31, 2024, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287161
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 31, 2024 — choose a marketed DIN from the same-category list.
Fosrenol · DIN 02287188 · 1000 mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2024 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Lanthanum
Brand(s): Fosrenol and Generics
DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet
Sevelamer Hydrochloride
Brand(s): Renagel
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Accel-Sevelamer
DOSAGE FORM/ STRENGTH: 800 mg tablet
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Fosrenol · DIN 02287188
Manufacturer: Takeda Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2024-07-31 · brand FOSRENOL · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE HYDRATE) 1000 MG · company Takeda canada inc · schedule Prescription
DIN 02287188: Fosrenol
Raw flags: notABenefit=Y, sec3=Y
Item: 401800008; group id 550; item number 1485; lccId None; manufacturer id TAK
Source form: Chew Tab; strength: 1000mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287188
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77261Interchangeable products
Nat-Lanthanum · DIN 02498774 · $4.8018
Shortage status: discontinued (July 31, 2024, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287188
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 31, 2024 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (V03AE): coverage varies; not interchangeable
Polystyrene sulfonate (Solystat): general benefit, not a benefit
Sevelamer carbonate (Renvela): not a benefit
Other drugs in the same formulary class (40:18 Potassium-Removing Resins) and how they are covered
Matched class: 40:18 Potassium-Removing Resins
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): POLYSTYRENE SODIUM SULFONATE
40:18 Potassium-Removing Resins
1 INDICATIONS
NAT-LANTHANUM (lanthanum carbonate dihydrate) is indicated as a phosphate binding agent in
patients with end stage renal disease on dialysis.
The use of lanthanum carbonate in controlled clinical studies beyond 2 years is limited. The risk versus
benefit from administration beyond two years should be carefully considered. (see WARNINGS AND
PRECAUTIONS, Bone, CLINICAL PHARMACOLOGY, Pharmacokinetics, Distribution, and CLINICAL
TRIALS, Bone Safety)
1.1 Pediatrics
Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not
authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (>65 years of age): Of the total number of patients in clinical studies of lanthanum
carbonate, 32% (538) were ≥65 years of age while 9.3% (159) were ≥75 years of age. No overall
differences in safety or efficacy were observed between patients ≥65 years of age and younger
patients.
https://pdf.hres.ca/dpd_pm/00072607.PDF
PM date: August 24, 2023
Source product: NAT-LANTHANUM; DIN 02498731; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Fosrenol · DIN 02287145
Shortage status: discontinued (2023-04-30, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287145
Fosrenol · DIN 02287153
Shortage status: discontinued (2024-06-10, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287153
Fosrenol · DIN 02287161
Shortage status: discontinued (2024-07-31, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287161
Fosrenol · DIN 02287188
Shortage status: discontinued (2024-07-31, reported by TAKEDA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287188
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Sevelamer Carbonate
Brand(s): Renvela
DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder
sachet
Updated: June 7, 2021
i) For the treatment of hyperphosphatemia associated with end-stage renal disease
(ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8
mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR
ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate
levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery
calcification.
466
Notes:
1. Calcium and phosphate levels provided to demonstrate sustained elevations should be
at least 4 weeks apart.
2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but
who experience adjusted serum calcium > 2.65 mmol/L must provide supporting
laboratory levels before treatment and while on treatment and should include the
dose(s) of calcium-based binder used.
Exclusion Criteria:
Sevelamer will not be reimbursed in the following cases:
Use in combination therapy with another funded non-calcium-based phosphate binder
(e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer
formulations)
Duration of approval: lifetime
On a case-by-case basis, requests may be considered for sevelamer under the EAP for a
patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65
mmol/L.
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.